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Diabetic retinal complications, including macular edema (DME) and proliferative diabetic retinopathy (PDR), are the leading
cause of new cases of blindness among adults aged 20–74. Chronic hyperglycemia, considered the underlying cause of diabetic
retinopathy, is thought to act ﬁrst through violation of the pericyte-endothelial coupling. Disruption of microvascular integrity
leads to pathologic consequences including hypoxia-induced imbalance in vascular endothelial growth factor (VEGF) signaling.
Several anti-VEGF medications are in clinical trials for use in arresting retinal angiogenesis arising from DME and PDR.
Although a review of current clinical trials shows promising results, the lack of large prospective studies, head-to-head therapeutic
comparisons, and potential long-term and systemic adverse events give cause for optimistic caution. Alternative therapies
includingtargetingpathogenicspeciﬁcangiogenesisandmural-cell-basedtherapeuticsmayoﬀerinnovativesolutionsforcurrently
intractable clinical problems. This paper describes the mechanisms behind diabetic retinal complications, current research
supporting anti-VEGF medications, and future therapeutic directions.
1.Introduction
Angiogenesis plays a critical role in the development of
diabetic complications, particularly those complications that
involve the eye. Diabetic retinopathy is widely considered
an inﬂammatory process [1]. It begins as vascular occlusion
and ischemia and may result in macular edema. The eye
adapts through vascular proliferation, which can cause
blindness through hemorrhage or ﬁbrosis. Complications
in diabetic patients are thought to be the pathological
result of a single underlying cause, hyperglycemia. Two
landmark studies in the 1990s, the Diabetes Control and
Complications Trial (DCCT) and the United Kingdom
Prospective Diabetes Study (UKPDS), showed that intensive
control of hyperglycemia can reduce the occurrence or
progression of retinopathy, nephropathy, and neuropathy in
both type one and type two diabetics [2, 3]. These ﬁndings
strongly suggest that hyperglycemia is at the root of diabetic
complications. However, strict control of hyperglycemia to
the levels outlined in these studies is extremely diﬃcult,
and diabetic complications continue to be a signiﬁcant and
sometimes life-ending reality in this population.
As obesity in the United States trends upward, so does
the prevalence of diabetes. In 2007, 23.6 million Americans,
7.8%, had diabetes including 23.1% of people older than
60. By 2030, that prevalence is expected to double [4].
For a person with diabetes, the overall risk of death is
twice that of nondiabetics at any age. Their average medical
expenditurewas2.3xhigherthannondiabetics,andtotalcost
was estimated at $174 Billion/year (CDC 2009).
Diabetes is the leading cause of new cases of blindness
among adults aged 20–74 years, and retinopathy causes
12,000 to 24,000 new cases of blindness each year. 25–50% of
patients with type I diabetes show some signs of retinopathy
within 10–15 years. This prevalence increases to 75–95%
after 15 years and approaches 100% after 30 years. 60% of
patients with type II diabetes show signs of nonproliferative
diabetic retinopathy after 16 years [5, 6].2 Journal of Ophthalmology
There is no question that diabetes is a signiﬁcant individ-
ual and public health concern. Uncontrolled hyperglycemia
is the foundation from which diabetic complications develop
and eventually result in poor health outcomes and qual-
ity of life. Although proven to be eﬀective [2], regular
examinations and strict hyperglycemic control are diﬃcult
to maintain and may result in alternative comorbidities.
Therapies that target the speciﬁc progression of DR seek to
limit the vision loss and other consequences of pathogenic
vascular insuﬃciency.
Currently the gold standard of treatment for PDR and
diabetic macular edema (DME) is panretinal and focal/grid
photocoagulation. Although this treatment is supported
by both the Early Treatment Diabetic Retinopathy Study
(ETDRS) and the Diabetic Retinopathy study [7, 8], it seeks
only to mitigate the results of the pathogenic process without
aﬀecting the underlying cause. Therapeutic interventions
that target the pathophysiological mechanism that leads
to PDR and DME can be more eﬀective in halting the
progression of these complications.
Vascular endothelial growth factor (VEGF) is integral in
the angiogenic process and implicated in retinal neovascular
development during PDR. Anti-VEGF treatments have been
approved by the US Food and Drug Administration (FDA)
for treatment of age-related macular degeneration (AMD),
and several anti-VEGF medications for DME and PDR are
currently in trials. This paper examines the mechanism
behind diabetic retinopathy and analyzes the potential
eﬀectiveness and limitations of anti-VEGF medications for
the treatment of diabetic complications.
2.DiabeticRetinopathy
Diabetic retinopathy (DR) can be classiﬁed into nonprolifer-
ative (NPDR) and proliferative (PDR) [9, 10]. The earliest
clinical signs of NPDR are microaneurysms and retinal
hemorrhaging. Development of cotton-wool spots, venous
bleeding, and intraretinal microvascular abnormalities are
hallmarks of progressive capillary profusion [5]. PDR is evi-
denced by the presence of new blood vessels on the surface of
the retina and optic disc in conjunction with further retinal
ischemia [11]. These new blood vessels become problematic
because they are fragile and highly permeable. They break
through the optic disc and grow along the surface of the
retina and into the scaﬀold of the posterior hyaloid face. The
vessels themselves do not impair vision, but are disrupted
easily by vitreous traction and hemorrhage into the vitreous
cavity or preretinal space [5]. The neovascularization is also
associated with a ﬁbrous component that when contracted
can lead to retinal detachment. This stage of PDR poses the
greatest threat to vision loss. Figure 1 shows the schematic
representation of the progression of diabetic retinopathy.
2.1. Role of the Pericyte. Both NPDR and PDR are thought
to be the reaction to increased vascular permeability due to
the breakdown of the endothelial-cell-pericyte interaction.
The ﬁrst vascular lesions that occur in the retina are the
thickening of the basement membrane, the endothelial
injury, the disruption of the tight junctions, and pericyte
apoptosis. Pericyte dropout may have profound repercus-
sion on capillary remodeling and will be the main factor
responsible for the ﬁrst abnormalities detected in clinical
examination by fundoscopy [35].
Pericytes represent a class of perivascular cells that
surround endothelial cells and perform functions on cap-
illaries similar to the ones that smooth muscle performs
on arterioles. They are heterogeneous with regard to their
origin, distribution, phenotype, and function [36]. Retinal
pericytes are associated with the vascular endothelium
through extended processes varying in length, arrangement,
and form, embedded in the capillary basement mem-
brane [37, 38]. The retina has the highest number of
pericytes in the body [39]. This interaction is critical in
maintaining the functional integrity of the capillary unit.
Pericytes regulate the capillary microenvironment through
three principal mechanisms: (1) communication with the
underlying endothelium by soluble mediators and cell-cell
contact, (2) synthesis, remodeling, and maintenance of the
basement membrane, and (3) regulation of microvascular
tone through Rho signaling [40]. All of these mechanisms
involve an overlapping array of biochemical and biome-
chanical signaling pathways [41, 42] that are not completely
understood.
Pericytes are also intricately involved in vascular devel-
opment and diﬀerentiation. During angiogenesis, nascent
microvessels are heralded by an actively motile and prolifer-
ative endothelium with an immature basement membrane.
This migratory and proliferative phase yields a primitive
capillary tube, followed by a microvascular maturation
phase marked by endothelial-FGF-2- and PDGF-dependent
recruitment of presumptive pericytes, occurring concomi-
tantly with basement membrane remodeling. Triggered by
endothelial contact, the presumptive pericyte then assumes
a mature contractile status by initiating expression of
its smooth muscle contractile protein repertoire [41–43].
Through the subsequent regulation of the capillary microen-
vironment, pericytes act to suppress endothelial growth
[44] and migration [45] .W o r k sd o n eb yH e l l s t r ¨ om et al.
and Lindahl et al. suggest that in order for pathological
neovascularizationtooccur,thequiescentendotheliummust
escape from its growth-arrested phenotype, perhaps actively
destabilizing and disengaging from its association with
pericytes as it reenters the cell cycle [40, 46, 47]. This is
consistent with observations of pericyte dropout seen in
pathological states, particularly diabetic retinopathy.
Several pathologies have been indicated that relate
hyperglycemia with pericyte dropout and eventual diabetic
retinopathy. Initially, it is important to note that pericytes
may exhibit dropout though apoptosis and/or migration,
both of which lead to the vascular changes that result in DR.
Apoptosis is a process of programmed cell death as a result of
cellular signaling. It is a very ordered and organized process
that minimizes damage to the surrounding tissues. Through
speciﬁc staining indicative of apoptosis, studies have shown
an apoptotic increase in retinal pericytes of isolated retinal
capillaries from diabetic patients [48].
However, this does not account for the total extent of
pericyte loss seen in experimental DR. Animal models haveJournal of Ophthalmology 3
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Figure 1: Schematic representation of the progression of diabetic retinopathy. Pericytes interact directly with the normal retinal capillary
endothelium (a) within the basement membrane via close contacts and gap junctions ensuring basal tone a(i) and growth arrest a(ii).
Persistent hyperglycemia leads to RhoGTPase induction of pericyte contraction b(i) causing reversal of EC growth arrest b(ii) and disrupted
matrix contact b(iii) prior to or in the absence of pericyte death/dropout. Basement membrane thickening and leaky, narrow capillaries
contribute to thrombosis, ischemia, and the ﬁrst detectible abnormalities of NPDR. In response to the resultant hypoxia, soluble mediators
of angiogenesis, such as VEGF, are released to develop collateral nutrient supply by forming nascent capillary tubes (c). These new blood
vessels are highly permeable and fragile and disrupt easily causing hemorrhage and the vision loss characteristic of PDR (d).
shown that pericyte apoptosis has been detected after 6
months of hyperglycemia [49] whereas signiﬁcant pericyte
loss is already detectible after three months of experimental
diabetes [50]. Pericyte migration has been suggested as
an alternative or additional mechanism of pericyte loss.
Pﬁster et al. 2008 show that hyperglycemia-induced pericyte
loss predominantly occurs on straight capillaries and is
accompanied by increased numbers of pericytes, migrating
fromthesamelocationintoperivascularposition[51].Other
studies have shown that pericyte detachment and migration
from underlying vessels into the perivascular parenchyma is
a feature of pericytes responding to diﬀerent kinds of stress
inducers. For example in brain capillaries, pericytes migrate
from capillaries as a result of ischemia, hypoxia, or injury
[52, 53]. Most likely pericyte loss includes both apoptosis
and migration. As mentioned earlier, pericytes are essential
tonascentangiogenesis.Theirmigrationinresponsetostress
maybethephysiologicalinitiationofangiogenesisinorderto
develop collateral nutrient supply. This process is actualized
in proliferative diabetic retinopathy as explained later in this
paper.
Although the mechanisms for pericyte loss have not been
fully determined, several studies have proposed plausible
initiation mechanisms that are here described.
Bax Expression. Bcl-2-associated X protein (Bax) is a mem-
ber of the Bcl-2 family. These proteins are well established
as inducers and integrators of survival and death signals.
The prosurvival family members can inhibit apoptosis
induced through cytotoxic insults, and the proapoptotic
membersgenerallyactthroughheterodimerizingprosurvival
proteins and antagonizing their eﬀects [12]. The relative
concentrations of these proteins within the cell are essential
for their impact on cell fate. Bax is a known proapoptotic
member of the Bcl-2 family.
Studies have shown that Bax overexpression is present
in diabetic retinal blood vessels. Speciﬁcally, Podest` ae ta l .
observed numerous focal increases in Bax staining localized
around pericyte nuclei and often associated with TUNEL-
positive fragmentation of the same nuclei [13]. They make
the association of high glucose, increased Bax, and increased
apoptosis, but cannot draw a molecular connection in situ.
This data suggests that hyperglycemia increases the levels
of Bax in retinal pericytes, tilting the cellular balance of
apoptosis regulators in a direction that leads to cell death
and eventual retinopathy. More research is necessary to
determine the molecular sequence of events.
TNF-α. Tumor necrosis factor alpha (TNF-α) is a pleiotrop-
ic cytokine involved in the regulation of immune cells during
systemic inﬂammation including initiation of apoptosis.
Elevated levels of TNF-α have been associated with the
early events of DR including the expression of adhesion
molecules [14]. Further studies have established the causal
link between TNF-α and diabetes-enhanced apoptotic loss
of microvascular retinal cells. Behl et al. showed inhibition
of TNF-α caused approximately 76–80% reduction in the
number of microvascular cells that expressed apoptotic
indicators [15]. TNF-α is a known inducer of apoptosis and
is shown here not only to be elevated in diabetic retinal4 Journal of Ophthalmology
microvasculature, but also to be directly involved in cell
death.
TGF-β. Transforming growth factor beta (TGF-β)i sam u l -
tifunctional cytokine that regulates signaling pathways. High
glucosehasbeenshowntoupregulateTGF-β1pr oductionin
cultured mesangial and glomerular cells [16]. High glucose
concentrationscanalsoinducebovineretinalpericytesapop-
tosis in vitro in association with increased concentrations of
TGF-β in the culture media [17]. Han et al. show that high
g l u c o s el e v e l ss t i m u l a t ep e r i c y t e st oe x p r e s sT G F - β,w h i c h
in turn upregulates βIG-H3 expression, resulting in RGD
signaling and induction of retinal pericytes apoptosis [18].
βIG-H3 is an extracellular matrix protein that is suggested
as being involved in cell growth, [19]c e l ld i ﬀerentiation,
[20] and cell adhesion [21]. It has also been shown to
mediateapoptosisthroughthereleaseofArg-Gly-Asp(RGD)
peptides [22], which in turn activate the caspase signaling
cascades in the cell cytoplasm [23]. Here, hyperglycemia
upregulates TGF-β causing an increase in βIG-H3 expression
which releases RGD peptides that act through the caspase
signaling pathway to induce pericyte apoptosis.
Ang/Tie. Tie-2 is a tyrosine kinase receptor primarily found
on endothelial cells; however, its RNA has also been reported
in pericytes [54]. Angiopoietins, Ang-1 and Ang-2, bind
to the Tie-2 tyrosine receptor and have been shown to
induce various results. Ang-1 binding to Tie-2 is suggested
to mediate the mobilization of hematopoietic stem cells to
the peripheral circulation [24] and the formation of mature
capillary networks by recruiting periendothelial cells such as
pericytes [25]. Ang-2 binding has been suggested to promote
smooth-muscle-cell-pericyte dropout, therefore loosening
contacts between endothelial cells and periendothelial cells
[26]. Cai et al. [27] show that Tie-2 receptors are expressed
in retinal pericytes and that Ang-2 protein is upregulated in
thediabeticretinaasaresponsetohyperglycemia.Theyshow
that Ang-2 plays a role in pericyte dropout and may later be
involved with pericyte proliferation in PDR. They also note
that Ang-1,2/Tie-2 interactions and downstream eﬀects are
dependent on a variety of diﬀerent factors that also depend
on the presence of other cytokines.
Table 1 further highlights the possible causes of pericyte
dropout. The mechanisms presented here are comprehen-
sive, but do not include all possible mechanisms. In actuality,
the pathway that leads to the eventual loss of pericytes
may include some combination of those above as well as
others not yet discovered. Also important to note is that
the biochemical process that links hyperglycemia and the
upregulation of various cytokines has yet to be described.
Alternatively, it has also been suggested that pericyte
mechanotransduction may be integral in the development
of pathological angiogenesis, negating the need for dropout
or death as initiation [40, 55]. Kotecki et al. implicate
calpain-dependant cleavage of talin as a critical step in
controlling pericyte contractility, perhaps via modulating
focal adhesion dynamics. They demonstrate that the strains
exerted by pericytes onto substrata can be suﬃcient to alter
normalbasementmembranefunctioningtherebyperturbing
the endothelial cell mechanical microenvironment [56].
This chemomechanically transduced insult on microvascular
contractility could potentially be responsible for endothelial
hyperproliferation inherent in diabetic retinal disease.
2.2. Angiogenesis in Diabetic Retinopathy. Impaired pericyte
function in conjunction with related basement membrane
thickening and dysfunction leads to the eventual devel-
opment of microaneurysms and dot intraretinal hem-
orrhages. These are two of the earliest abnormalities
detectable through ophthalmoscopic examination. Retinal
leakage ensues and vasoconstrictive agents lead to a hypoxic
environment. Eventually capillaries are constituted only
of tubes of thickened basement membrane, and being
highly thrombogenic, lead to greater ischemia [35, 57]. The
worsening ischemia results in the shift from nonproliferative
diabetic retinopathy to proliferative diabetic retinopathy via
angiogenesis.
Platelet-Derived Growth Factor. Platelet-derived growth fac-
tor (PDGF) is a 35kDa protein originally puriﬁed from
platelets and now recognized in several cell types including
the retina [58]. It acts as an important signaling molecule
including several diﬀerent roles in angiogenesis. Most stud-
ied are the hetero- and homodimeric versions, PDGF-AA,
PDGF-BB, and PDGF-AB and their structurally related pro-
tein tyrosine-kinase receptors [59]. Normal PDGF-receptor
interaction assists angiogenesis by enhancing pericyte pro-
liferation and migration most likely through increasing
expression of Ang-1 and the resulting signaling cascade
[60, 61]. Retinal pericytes have been shown to exhibit the
proliferation and chemotaxis in response to PDGF [62],
which is also implicated in PDR. Increased levels of PDGF
have been identiﬁed in the vitreous ﬂuid in patients with
PDR [63]. Hypoxia and hyperglycemia, both characteristic
of PDR, are shown to increase the production of PDGF
in cultured bovine retinal pericytes [64]. PDGF acts as a
survival factor in retinal pericytes. Experiencing the hypoxia
and ischemia characteristic of diabetic retinopathy, PDGF
transcription increases and contributes to angiogenesis.
PDGF is necessary for normal retinal vascularization, but
its overexpression is a key mediator in the pathogenesis of
proliferative diabetic retinopathy.
Fibroblastic Growth Factor. Fibroblastic growth factor (FGF)
is a family of structurally related heparin-binding proteins
known to be potent angiogenesis inducers [65]. It comes
in both a basic (bFGF) and acidic (aFGF) form, which
act to stimulate endothelial cell migration, proliferation,
and microvessel tube formation in cell types that derive
from the embryonic mesoderm and ectoderm [66, 67].
FGF in the retina has been reported in ganglion inner and
outer nuclear layer, basement membrane of the Muller cells,
blood vessels, and retinal pigment cells [68, 69]. Despite its
known angiogenic activity and presence in retinal cells, the
pathologic activity of FGF in DR has yet to be determined.
Hepatocyte Growth Factor. Hepatocyte growth factor (HGF)
is 90kDa cytokine synthesized in the liver that is activeJournal of Ophthalmology 5
Table 1: Possible causes of pericyte dropout.
Factors Evidence
BAX expression
(i) Proapoptotic member of the Bcl-2 family [12].
(ii) Increased levels shown in retinal pericyte nuclei [13].
(iii) Shift of the balance toward pericyte apoptosis.
TNF-α
(i) Cytokine involved in the regulation of immune cells during systematic inﬂammation including apoptosis
[14].
(ii) Elevated levels of TNF-α are associated with the early events of DR [14].
(iii) Inhibition of TNF-α shown to cause a large reduction in the number of microvascular cells that expressed
apoptotic indicators [15].
TGF-β
(i) Cytokine that regulates signaling pathways.
(ii) High concentrations evidenced in response to hyperglycemia in pericytes and other vascular cells [16, 17].
(iii) Increased TGF-β leads to βIG-H3 and RGD signaling that activates the capsase signaling pathway leading
to apoptosis [18–23].
Ang/Tie (i) Ang-2/Tie-2 binding shown to produce downstream pericyte apoptosis [24–26].
(ii) Ang-2 is upregulated in retinal pericytes in response to hyperglycemia [27].
in regulating cell growth, cell motility, and morphogenesis
of various types of cells [70]. It acts on epithelial and
endothelial cells through a paracrine interaction with a high
aﬃnity c-Met tyrosine-kinase surface receptor [71]. High
concentrations of HGF have been recognized in serious PDR
with coexisting ﬁbrovascular proliferation [72]. Although
present in retinal cells, the linking mechanism to PDR and
conclusive evidence have not been discovered.
Role of VEGF. In addition to the factors described above,
vascular endothelial growth factor (VEGF) plays a critical
roleinbothphysiologicalandpathologicalangiogenesis.The
human VEGF gene is organized into eight exons and is
localized in chromosome 6p21.3. Alternative exon splicing
results in the generation of four main isoforms having 121,
165, 189, and 206 amino acids, respectively. VEGF165 is
the predominant molecular variant as a heparin-binding
homodimeric glycoprotein of 45kDa [73–75].
VEGF exerts its action through two high-aﬃnity tyrosine
kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1).
Evidence suggests that VEGFR-2 is the major mediator of the
mitogenic, chemotactic, angiogenic, and increased perme-
ability eﬀects of VEGF [76]. This ligand receptor interaction
has been shown to stimulate microvascular endothelial
cell proliferation [76] and EC migration [77], inhibit EC
apoptosis [78], and induce angiogenesis [79].
Downstream eﬀects of the upregulation of VEGF include
increases in proinﬂammatory mediators like intercellular
adhesion molecule 1 (ICAM-1). Increased presence of
ICAM-1 is associated with leukostasis and vascular perme-
ability recognized in animal diabetic retinopathy [80–82].
These ﬁndings substantiate the signiﬁcance of inﬂammation
in the progression of DR.
There are several mechanisms that have been shown to
participate in the regulation of VEGF gene expression. Of
particular signiﬁcance in the pathogenesis of PDR is the
upregulation of VEGF in response to hypoxia. VEGF mRNA
expression is rapidly and reversibly induced by exposure to
low pO2 in a variety of pathophysiological circumstances
[83, 84]. This is mediated through hypoxia-inducible factor
1 (HIF-1) [85]. HIF-1 is a basic, heterodimeric, helix-loop-
helix protein, transcription factor composed of the consti-
tutively expressed HIF-1β, and the oxygen-sensitive HIF-1α
subunits [86]. In appropriately oxygenated tissues, HIF-1α is
broken down. In hypoxic conditions, the breakdown of HIF-
1α is inhibited and it begins to build up and dimerize with
HIF-1β. This complex then binds to DNA, helps to recruit
coactivators, and activates transcription of its target genes,
including VEGF [87, 88].
As a survival response to the ischemic environment
created by NPDR, transcription of VEGF increases, leading
to endothelial cell proliferation, progenitor cell migration,
and pathological angiogenesis. Increased intravitreal levels
of VEGF have been shown in patients with DME and PDR
[89], implicating VEGF as a signiﬁcant contributor to the
pathogenic process and an important focus for intervention.
3.Anti-VEGFTreatments
There are four anti-VEGF pharmacologic agents commer-
cially available and in trials for their use as treatment
for DME and PDR. Pegaptanib (Macugen, OSI/Eyetech,
Melville, NY, USA) is a pegylated aptamer that targets
VEGF165, inhibiting its endothelial mitogenic activity and
vascular permeability eﬀects [90, 91]. Based on the results
of the VEGF Inhibition Study in Ocular Neovasculariza-
tion (VISION) trial, the FDA-approved Macugen for the
treatment of neovascular AMD [92]. Although shown to
be eﬀective, pegaptanib therapy has been replaced by the
development of nonselective anti-VEGF therapies.
Both bevacizumab (Avastin; Genetech, San Francisco,
CA, USA) and ranibizumab (Lucentis; Genetech) are
humanizedmonoclonalantibodies,fulllengthandfragment,
respectively, that bind all VEGF isoforms. The FDA has
approved Lucentis for neovascular AMD, and Avastin is
being used oﬀ-label for treatment of various ocular diseases.
The ﬁnal anti-VEGF treatment is the VEGF Trap-
Eye (Regeneron Pharmaceuticals, Inc., Tarrytown, New6 Journal of Ophthalmology
York, NY, USA and Bayer Healthcare Pharmaceuticals,
Berlin, Germany). It is a 115kDA recombinant fusion
protein consisting of the VEGF-binding domains of human
VEGFR-1 and VEGFR-2 fused to the Fc domain of human
immunoglobulin-G1 [93]. It acts to sequester VEGF, bind-
ing preferentially over the physiological receptors. Animal
studies have shown intravitreal VEGF Trap-Eye has theoretic
advantages over other anti-VEGF treatments, including
longer half-life in the eye and a higher binding aﬃnity to
VEGF-A and related proteins, placental growth factors 1 and
2[ 94, 95]. Trap-Eye is currently in phase two trials.
3.1. Clinical Trials and Safety Implications. Recently pub-
lished prospective studies of anti-VEGF medications for
both DME and PDR show the clinical eﬀectiveness of these
medications and point to possible adverse events. Studies
thatfocusedontheeﬀectivenessofpegaptanibinDMEcome
from the work of the Macugen Diabetic Retinopathy Study
Group [28]. The study involved 172 patients, randomized
into four arms: 3mg intravitreal pegaptanib, 1mg, 3mg, or
sham given at weeks 0, 6, and 12. Eyes in the pegaptanib
groupshowedmoreimprovementovertheshameyes,partic-
ularly in the 0.3mg group. The improvement included better
visual acuity, more reductions in central retinal thickness,
and less need for macular laser photocoagulation [96]. These
study patients had no previous history of treatment for
DME, and subsequent studies have shown that treatment-
na¨ ıve eyes respond better to anti-VEGF therapy [32, 97].
Trials investigating the eﬀectiveness of pegaptanib for the
treatment of PDR have yet to be published.
A recent trial of ranibizumab has shown its eﬀectiveness
for the treatment of DME. Nguyen et al. conducted the
ranibizumab for Edema of the Macula in Diabetes (READ-
2) Study to investigate treating DME [98]. The group ran-
domized 126 eyes into three groups: the ﬁrst received 0.5mg
intravitreal ranibizumab at baseline and months 1, 3, and 5;
the second underwent focal/grid laser photocoagulation at
baseline and again at three months if needed; the third group
underwent laser at baseline and ranibizumab injections at
baseline and 3 months. Their primary endpoint was an
improvement in best-corrected visual acuity (BCVA) at six
months then throughout a follow-up period lasting to 12
months. At six months, the ﬁrst group showed the largest
statistically signiﬁcant improvement in BCVA, +7.24 letters
versus −0.43 and +3.80 letters for groups 2 and three,
respectively. After two years the ﬁrst group still showed
the largest improvement in BCVA; however, there was little
change between the six-month and two-year results. The
authors attribute this lack of change to the heterogeneity of
patients with DME and note that the post-six-month regime
may not have been ideal for all patients [98]. They suggest
that perhaps some combination of more frequent injections
or greater amounts will provide better control over edema.
Table 2 further describes the considerable current clinical
activity regarding the role that anti-VEGF therapies may play
in DME.
Bevacizumabis,forbothDMEandPDR,thebeststudied
anti-VEGF medication due to availability and a cost diﬀer-
ence of US$150 versus US$1600 for a dose of ranibizumab
[99]. Nicholson and Schachat review the clinical trials and
results of bevacizumab for both DME and PDR [96]. They
note beneﬁcial short-term eﬀects on treatment of na¨ ıve eyes
for DME and laser-refractory DME including improvements
in both visual acuity and central macular thickness. In trials
pertaining to PDR, treatment with bevacizumab has been
promising in areas of decreasing leakage in neovascular
lesions, showing a substantial eﬀect on new vessels. Mirshahi
et al. conducted the largest of the clinical studies in patients
with bilateral PDR with high-risk characteristics [100]. In
one eye they received 1.25mg bevacizumab injection with
scatter laser treatment according to the ETDRS protocol and
the other eye received a sham injection with the scatter laser
treatment. After six weeks, almost 90% of the intervention
eyes had complete regression of neovascularization versus
25% in the sham group. Although remarkably eﬀective, the
results were short lived and there was no diﬀerence in the
twogroupsafter16weeks.Otherreviewedtrialsshowsimilar
results. Most notably absent from the available clinical trials
are long-term, well-designed studies that involve multiple
dosing and comprehensive investigation of potential adverse
e v e n t s .T h i sm a yb ed u et oal a c ko fa p p r o p r i a t es t u d y
techniques.
The VEGF Trap-Eye is the least tested anti-VEGF
treatment. The DME and VEGF Trap-Eye: Investigation
of Clinical Impact (DA VINCI) study compares diﬀering
doses of the intervention with standard macular laser
treatment [101]. All Trap-Eye treatment arms of the study
showed signiﬁcantly better mean visual acuity outcomes and
greater mean reductions in retinal thickness over the 24-
week period. These results are similar to those shown by
the three other treatment interventions although no direct
c o m p a r i s o n sh a v eb e e np e r f o r m e d .
Each therapy seems to show some beneﬁcial eﬀect to
treatment endpoints like best-corrected visual acuity and
central macular thickness, but an investigation of safety and
adverse events taking into consideration the limitations of
current trials is essential.
Much of the safety information from these interventions
comes from their use and study of age-related macu-
lar degeneration. These studies are generally ineﬀective
and underpowered at detecting adverse events, and larger
prospective trials with methodological surveillance are still
needed. For pegaptanib, the VISION trial attributed no
systemic side eﬀects to treatment over the course of the study
[92].Forranibizumab,theANCHOR[102,103]andFOCUS
[104, 105] trials reported small rates of endophthalmitis and
no serious nonocular adverse events. Pooled data from the
MARINA, ANCHOR, and PIER studies showed a slightly
increased rate of vascular events, which may be clinically
irrelevant given the 2-year safety data [96].
Asbefore,studiesinvolvingbevacizumabyieldthelargest
amount of information. A large retrospective study of
1,173 patients who received intravitreal bevacizumab yielded
systemic adverse events: seven cases of acute hypertension,
six cerebral vascular accidents, ﬁve myocardial infarcts, two
iliac artery aneurisms, and two toe amputations. There
were several ocular adverse events: seven cases of endoph-
thalmitis, seven cases of tractional retinal detachment, fourJournal of Ophthalmology 7
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cases of uveitis, and a less signiﬁcant representation of
others [106]. These results are similar to those found from
other bevacizumab studies and those of other anti-VEGF
agents. Some additional systemic eﬀects have been recog-
nized in bevacizumab use in cancer therapy including arte-
rial thromboembolism, gastrointestinal perforation, hem-
orrhage, hypertensive crisis, and nephritic syndrome [107,
108]. An additional study also showed that bevacizumab
when used systemically with chemotherapeutic agents can
increase the risk of thromboembolic events twofold over
chemotherapy alone [109].
Other adverse events important to note are the develop-
ment of tractional retinal detachment (TRD) and the possi-
bility of systemic drug entry. Clinical trials of bevacizumab
for treatment of PDR show increased risk of TRD following
a rapid retinal neovascular regression [110–112]. Further,
Averyetal.founddecreasedneovascularleakageinuntreated
“fellow” eyes raising the possibility that after injection of
1.25mg, systemic inhibitory concentrations are achieved
[113]. As systemic anti-VEGF therapy may be responsible
for the increased risk of thromboembolic events seen in
cancer therapy, an unintended trespass across the blood-
retinal barrier may have far-reaching consequences.
4. Discussion and Conclusions
The diabetic retinopathy cascade begins with chronic hyper-
glycemia aﬀecting the normal progression of glycolysis.
The downstream eﬀect includes pericyte dropout and/or
deregulated contractility, the disruption of microvascular
integrity, and a hypoxia-induced imbalance in VEGF signal-
ing.Thisimbalanceleadstotheuncontrolleddevelopmentof
fragile and highly permeable nascent blood vessels prone to
hemorrhageandvisualocclusion.Therapiesthatintervenein
this inﬂammatory process must balance the beneﬁcial eﬀects
of reduced neovascularization with the requirement not to
harm the normal vasculature or the associated functional
supportive epithelial and neuronal cells.
VEGF is anessentialmoderator ofthe angiogenic process
and implicated in the development of diabetic retinopathy.
Anti-VEGF therapy has been developed to reduce retinal
neovascularization. The therapies that fall under the anti-
VEGF umbrella have been shown to increase visual acuity in
DME and reduce the development of nascent blood vessels
in PDR when compared to the standard photocoagulation.
Although eﬀective, these therapies are not without fault.
Most studies are small and suﬀer from a very focused
design. Large, long-term prospective studies that involve
close monitoring for adverse events will greatly advance the
current researchavailable. However, these studies may not be
feasible in the context of pharmaceutical development and
cost.
The adverse events that have emerged from current
research raise some cause for concern. Particularly, a viola-
tion of the blood-retinal barrier by anti-VEGF agents can
have catastrophic systemic eﬀects. Further, the long-term
eﬀects of these agents are still unknown. VEGF plays such
ac r i t i c a lr o l ei nt h ee y ea sw e l la ss y s t e m i c a l l y ,s i m p l y
inhibiting its action universally may cause signiﬁcant adverse
events after years of use.
Alternatives to photocoagulation and anti-VEGF injec-
tions are being investigated. They include therapies that
targetthemechanismsbehindpericyteapoptosisanddetach-
ment. TNF-α inhibition could reduce endothelial damage
andpericyteapoptosis[15].InhibitionoftheβIG-H3protein
could also serve as a future target [18]. Targeted regulation of
angiopoietin isoforms in the Ang/Tie system may also oﬀer a
therapeutic approach to diabetic complications.
The use of corticosteroids has also emerged as a potential
treatment targeting the inﬂammatory cascade. Clinical trials
of intravitreal triamcinolone for patients with diabetic
macular edema have shown little long-term beneﬁt relative
to focal/grid photocoagulation [114]. The trials have also
indicated the signiﬁcant presence of adverse events such
as increased intraocular pressure and increased incidence
of cataracts. Ozurdex (Allergan), an intravitreally injectable
dexamethasone implant, has shown beneﬁcial eﬀects in the
treatment of DME [115]. Further noninferiority trials are
necessary before widespread adoption.
Although further investigation into the contractility
apparatus of the pericyte endothelial interaction is necessary,
it presents a novel target for therapeutic intervention. Future
developments that act on the calpain-dependant cleavage
of talin as an integral step in pericyte contractility could
preferentiallyeliminatetheneedforanti-VEGFintervention.
Alternatively, recent research investigating hemangioma-
derived stem cells (HemSCs) has shown diﬀerentiation of
HemSCs to pericytes through the NOTCH family ligand
JAGGED1. This represents original evidence for a human
postnatalvascularprogenitorcell[116].Althoughsigniﬁcant
further research is needed, injecting HemSCs into a retino-
pathic eye can bestow the stability and regulation of healthy
pericytes in place of ones damaged by hyperglycemia.
Additional current reviews highlight emerging therapeu-
tic possibilities and future areas of research [117, 118].
The retinal complications that arise from chronic hyper-
glycemia have a signiﬁcant impact on the lives of diabetic
patients. Amelioration of these complications and their
damaging eﬀects will greatly beneﬁt these patients and
impact overall healthcare. Anti-VEGF therapies inhibit an
essential mediator in the DR cascade and have been eﬀective
in causing regression of neovascularization and improving
visual acuity. However, the evidence shows that complete
inhibition of VEGF isoforms leads to known adverse events
and unknown systemic and long-term consequences. We
urge caution at the use of anti-VEGF agents for DME and
PDR because the safety and eﬃcacy of these drugs has yet
to be fully established. Larger controlled trials are necessary
as the vetting process continues. Also essential is the devel-
opment of alternative therapies that target the pathogenic
process leading to neovascularization. Focused therapies
involving pericyte-endothelial-cell contractile apparatus and
HemSCs are novel avenues with great potential. Due to
the complexity of angiogenesis in DR, no one therapy
will likely be perfect. However continued research into
the pathogenesis and mechanical mechanisms behind this10 Journal of Ophthalmology
vascular insuﬃciency will highlight innovative opportunities
for intervention.
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